Accelerating Innovation in AI & Biotech
Where Artificial Intelligence Meets Regenerative Medicine and Psychiatry
AiSIMP is an IP-driven R&D company dedicated to transforming healthcare through artificial intelligence and biotechnology.
We develop groundbreaking solutions—internally and in strategic partnerships—that shorten time-to-market for new therapies by up to 50%.
From precision psychiatry software (Psynopsis.ai) to next-generation regenerative medicine platforms (UltraFibrin™), we use a first-principles approach to solve complex medical challenges faster and more effectively than ever before.
Why Choose AiSIMP?
Proprietary AI Systems
We build and own the IP for advanced AI platforms that accelerate clinical research and product development.
Cutting-Edge Tech Pipeline
We apply large-scale data analytics, deep learning, and computational biology to discover new frontiers in regenerative medicine and mental healthcare.
Strategic Partnerships
Our collaborations with leading biotech, healthcare, and regulatory experts give us a unique edge in launching and scaling innovations.
Our Technology Portfolio: From AI-Driven Psychiatry to Advanced PRP
Psynopsis.ai
A robust AI platform that personalizes psychiatric care by analyzing patient data, clinical trial results, and real-world evidence.
Reduces misdiagnosis, streamlines treatment planning, and increases patient engagement by up to 35% in pilot studies.
Combines machine learning models with curated datasets for rapid hypothesis testing—cutting research cycles from years to months.
Ultrafibrin
A robust AI platform that personalizes psychiatric care by analyzing patient data, clinical trial results, and real-world evidence.
Reduces misdiagnosis, streamlines treatment planning, and increases patient engagement by up to 35% in pilot studies.
Combines machine learning models with curated datasets for rapid hypothesis testing—cutting research cycles from years to months.
R&D APPROACH
Cutting Development Timelines in Half
AiSIMP’s R&D engine is fueled by advanced computational models, real-world clinical data, and AI-driven automation.
By harnessing predictive analytics and in silico simulations, we can test millions of potential formulations or therapeutic approaches—virtually—before we move into lab trials.
Hypothesis Generation
AI combs through biomedical literature and patent databases to propose new angles.
Simulation & Modeling
Animal models and patient data feed into iterative simulations, drastically reducing trial-and-error in the lab.
Scaled Prototyping
Once validated, we prototype at scale, often seeing a 50% reduction in overall time-to-market.
Regulatory Alignment
We work closely with partners to ensure that each phase meets the FDA and USDA guidelines—paving a clearer path to approval.
Partnerships
Accelerate Innovation
Through Collaboration
Seeking Strategic Alliances for Faster Clinical & Commercial Success
Our network includes research hospitals, academic institutions, and biotech pioneers who collaborate to fast-track clinical trials and regulatory approvals.
We selectively partner where our AI-driven platforms can magnify the impact—whether optimizing psychiatric treatment protocols or refining PRP formulations for advanced aesthetics.
How to Partner with Us
Joint R&D
Integrate AiSIMP’s AI frameworks into your research.
Co-Commercialization
Leverage our expertise to bring your product to market swiftly.
Licensing & IP
Access AiSIMP’s patented technologies and trademarks for global expansion.
Ready to grow?
Let's create your success story.
Our AI-driven marketing strategies have helped clinics like yours boost patient flow and expand their reach. Curious about what we can do for you?
Contact us today for a free consultation and discover how we can transform your practice's growth.
